03:16 AM EST, 11/13/2025 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Thursday it priced a private placement of $700 million principal amount of 0% convertible senior notes due 2030.

The initial purchasers have been granted a 13-day option to purchase up to $70 million additional amount of notes.

Net proceeds, estimated to be about $682.8 million to $751.2 million, will be used to fund the repurchase of 0% convertible senior notes due 2026, and for general corporate purposes, the company said.

The notes will be convertible at an initial rate of $98.10 per share.

The sale is expected to close on Nov. 17, subject to customary closing conditions.

The company also said it agreed to buy from certain holders $200 million principal amount of its outstanding 0% convertible senior notes due 2026.